Both PRP and umbilical cord biologics get marketed under the same broad heading of “regenerative medicine.” They’re not the same thing. The differences are worth understanding before any consultation.
What PRP is
Platelet-Rich Plasma is made from the patient’s own blood. A small volume is drawn, then spun in a centrifuge to concentrate the platelets and the growth factors they carry. The resulting concentrate is then placed at the target site.
PRP has been around for decades. It works by triggering a healing response in tissue — essentially recruiting the body’s repair machinery to a specific location and providing a concentrated dose of platelet-derived signaling molecules to support that response.
Where PRP’s collagen profile sits
PRP is almost entirely Type 1 collagen-supportive. When the body responds to PRP, the new tissue it builds is predominantly Type 1. That’s genuinely useful for tendons, ligaments, fascia, and other Type 1-rich connective structures.
For cartilage, however — which depends on Type 2 collagen — the response is more limited. PRP can support the surrounding environment, but it doesn’t supply Type 2 collagen building blocks directly.
The duration limitation in PRP research
Studies on PRP have consistently shown improvement in roughly the 3- to 4-month range. After that window, results commonly fade, and most patients eventually need repeat protocols to maintain effect.
This isn’t a flaw in PRP — it’s the realistic profile of what an autologous, single-collagen-type intervention typically delivers.
What umbilical cord biologics are
Umbilical cord-derived biologics, including Wharton’s Jelly products, are sourced from healthy, full-term C-section deliveries with consenting mothers and processed in FDA-registered, AATB-certified facilities. They are classified as 361 HCT/P allografts.
This tissue contains a more comprehensive structural profile: Types 1, 2, AND 3 collagen, plus hyaluronic acid, plus a range of native signaling proteins. It’s also considered immune-privileged, meaning the body engages with it without mounting the same kind of inflammatory immune response it might mount against other foreign material.
What the published research has shown
A 2022 published study on a single Wharton’s Jelly application in joint applications found durable results out to six months. Notably, that study was the only biologic study at the time to show statistically significant reductions in both pain medication use AND anti-inflammatory medication use at the six-month mark.
Research on combination protocols — for example, bone marrow concentrate plus Wharton’s Jelly MSCs — has shown robust collagen growth across Types 1, 2, and 3 in joint models. That’s the full structural spectrum joints actually need.
Where each may fit best
Both have a role. PRP may be appropriate for certain situations, particularly in younger, healthier patients with more limited tissue damage — those whose own biology is doing more of the heavy lifting and who don’t need the broader collagen profile.
More complex situations — older patients, more significant structural damage, multiple compounding health factors, conditions where multiple collagen types are involved — may benefit from a more comprehensive structural profile that doesn’t depend as heavily on the recipient’s own cellular vigor.
The right question isn’t “which is better”
Comparing PRP and umbilical cord biologics by asking “which one is better” misses the point. The right question is: which one matches the tissue, the structural problem, and the cellular environment of the specific patient?
A thorough consultation considers what tissue is involved, what collagen profile that tissue requires, the patient’s age and health context, the patient’s goals, and what realistic durability looks like. Sometimes the answer is PRP. Sometimes it’s an allogeneic biologic. Sometimes it’s a combination protocol. Sometimes the most honest answer is that neither is the right intervention right now.
Why the framing matters
Both PRP and 361 HCT/P allografts are regulated under FDA frameworks. Neither treats disease. Both work by supplying the body with specific structural materials it can use to support its own natural repair processes. Knowing the differences in collagen profile, sourcing, and immune characteristics simply puts patients in a much better position to ask the right questions — and to evaluate the answers they get.
REQUIRED DISCLAIMER
Educational content only. The information presented in this article is for general informational and educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. RegenHaus uses 361 HCT/P regenerative biologics, which are not FDA-approved to treat or cure any condition. Individual results vary. Please consult a licensed medical provider before considering any therapy or making changes to your health regimen.
